The professor of neurology at the University of Cincinnati discussed why disparities persist in secondary stroke prevention and how growing awareness of social determinants of health is helping to ...
In recent news, the FDA granted Fast Track designation to remlifanserin (ACP-204; Acadia Pharmaceuticals), an investigational selective serotonin 5-HT2A receptor inverse agonist, for the treatment of ...
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Olfactory dysfunction, dysautonomia, mood disturbance, and motor deficits disproportionate to dopaminergic denervation may serve as markers of amyloid-β positivity in newly diagnosed Parkinson disease ...
Xenon Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for azetukalner (XEN1101) as adjunctive treatment for focal seizures in adults with epilepsy, based on ...
Xenon Pharmaceuticals submitted an FDA new drug application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy. Marketed as Fayuvi, the 1-time AAV9 ...
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...
The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare ...
Foundational health behaviors reduce migraine burden, but frequent or disabling attacks commonly require preventive treatment ...
The American Academy of Neurology (AAN) and American Headache Society (AHS) have issued an updated practice guideline on ...
FDA approval of apitegromab introduces a muscle-targeting approach to SMA treatment, with phase 3 data demonstrating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results